Pulsenmore Expands into Fertility Care with CE-Approved Home Ultrasound System
Event summary
- Pulsenmore Ltd. has completed CE European registration for its Pulsenmore FC home ultrasound system for follicular monitoring in IVF and fertility preservation treatments.
- The system enables patients to self-perform ultrasound scans at home, reducing the need for repeated clinic visits.
- Over 1.15 million assisted reproduction treatment cycles were reported in Europe in 2023, with more than half involving treatments requiring ovarian stimulation.
- A clinical study at Rabin Medical Center demonstrated high agreement between home and in-clinic ultrasound scans, with high satisfaction among patients and clinical staff.
The big picture
Pulsenmore's expansion into fertility care marks a strategic shift from prenatal monitoring to a broader women's health platform. The CE approval for Pulsenmore FC positions the company to capitalize on the growing demand for remote care solutions in fertility treatments, where repeated ultrasound examinations are crucial. This move aligns with industry trends towards decentralized healthcare models, aiming to improve patient convenience and clinic efficiency.
What we're watching
- Market Expansion
- How Pulsenmore will leverage its CE approval to penetrate the European fertility care market and establish partnerships with fertility centers and healthcare systems.
- Regulatory Compliance
- Whether Pulsenmore can maintain and expand regulatory approvals in additional jurisdictions to support its global expansion strategy.
- Commercial Success
- The pace at which Pulsenmore can commercialize Pulsenmore FC and achieve market acceptance, given the competitive landscape and patient adoption rates.